Who bills the most Injection, ocrelizumab, 1 mg (J2350) to Medicare in New Jersey?
Medicare Part B FFS · CY2024 · as published by CMS3 physician groups billed Injection, ocrelizumab, 1 mg (J2350) to Medicare fee-for-service in New Jersey in 2024; independent (non-hospital-affiliated) groups deliver 0%.
J2350 — Injection, ocrelizumab, 1 mg · Source: CMS Medicare Physician & Other Practitioners PUF (Part B), CY2024 release. Medicare fee-for-service only.
Snapshot covers the whole New Jersey market — the table below shows the top 100 groups (free tier).
Medicare fee-for-service covers 59% of Medicare in New Jersey; Medicare Advantage penetration 32% → 41% since 2020.
| # | Physician group | City | St | Specialty | Providers | J2350 svcs | Share* | Phone |
|---|---|---|---|---|---|---|---|---|
| 1 | BROMLEY NEUROLOGY PC | AUDUBON | NJ | NEUROLOGY | 3 | 39,001 | 60.7% | (856) 546-2300 |
| 2 | HUNTERDON NEUROLOGY, PA | FLEMINGTON | NJ | NEUROLOGY | 3 | 17,400 | 27.1% | (908) 894-7222 |
| 3 | CAPITAL HEALTH MEDICAL GROUP | PENNINGTON | NJ | NURSE PRACTITIONER | 439 | 7,800 | 12.1% | (609) 537-6000 |
*Share of New Jersey's disclosed Medicare-FFS services for J2350, counted once per clinician. Volume is placed in the state it was billed from, so this page ranks the groups actually billing J2350 in New Jersey — including groups registered elsewhere ("City" is each group's registered location). Group figures sum clinicians affiliated with exactly one group; clinicians in several groups are listed in each group's drill-down but not volume-attributed to any single group.
How to read this. Figures are Medicare fee-for-service only — not all-payer — from the CMS Medicare Physician & Other Practitioners Public Use File (Part B), CY2024 release. CMS suppresses any provider×code row under 11 beneficiaries, so a missing group means "suppressed," never zero. "Charges" are provider-submitted amounts, not payments. Groups are ranked by measured service volume attributed to clinicians in exactly one group — clinicians affiliated with several groups are listed in rosters but never volume-attributed to a single group — a direct read of the public record, not a rating or quality score. Full method: Methods & Sources.
Comparing against an all-payer estimate?
These are exact counts from Medicare fee-for-service claims — roughly a third to half of most procedure markets, depending on payer mix. Modeled all-payer databases project the remainder statistically; we publish the audited floor and label it as such. Same market, different denominator. How the numbers reconcile →